catalyst

Monotherapy of an NMDA Enhancer for Schizophrenia — primary completion

as of 2026-07-01
Monitor thisAsk about this
at a glance
2027-09 · Estimated (est.) — Registry-estimated date, not yet actual.
Synthesized from structured facts only — each point cited above.

Event

What
Monotherapy of an NMDA Enhancer for Schizophrenia — primary completion
Type
Trial Readout
Date
2027-09
Date type
ESTIMATED est.
Phase
Phase 2
Registry-estimated date, not yet actual. This date is directional and must not be read as settled.
relationships
The graph out of here
trial
Monotherapy of an NMDA Enhancer for Schizophrenia
trial